Skip to main content
# Table 1 Human samples

From: The apolipoprotein receptor LRP3 compromises APP levels

Age (y) | Gender | PM (h) | SP | ApoE | |
---|---|---|---|---|---|

MA NFT
| |||||

0 | 46 | f | 9.5 | 0 | ɛ2/ɛ3 |

46 | m | 15 | ɛ3/ɛ4 | ||

47 | m | 5 | ɛ3/ɛ3 | ||

49 | m | 7.5 | ɛ3/ɛ3 | ||

50 | m | 17 | ɛ3/ɛ3 | ||

52 | m | 5 | ɛ3/ɛ3 | ||

52 | f | 6 | ɛ4/ɛ4 | ||

53 | m | 7.5 | ɛ3/ɛ3 | ||

56 | m | 4 | ɛ2/ɛ3 | ||

59 | m | 6,5 | ɛ3/ɛ3 | ||

60 | f | 11.5 | ɛ3/ɛ3 | ||

AD NFT
| |||||

Braak I | 53 | m | 6.25 | A | ɛ3/ɛ4 |

64 | m | 8.5 | 0 | ɛ3/ɛ3 | |

67 | m | 14.5 | 0 | ɛ3/ɛ3 | |

68 | m | 11 | 0 | ɛ2/ɛ3 | |

Braak II | 57 | m | 4.5 | 0 | ɛ3/ɛ4 |

60 | f | 9.5 | A | ɛ3/ɛ3 | |

65 | m | 16.5 | 0 | ɛ3/ɛ3 | |

67 | m | 7.25 | 0 | ɛ3/ɛ4 | |

69 | m | 3.5 | A | ɛ3/ɛ4 | |

72 | m | 6.25 | A | ɛ3/ɛ4 | |

74 | m | 5.5 | A | ɛ2/ɛ3 | |

78 | m | 16 | 0 | ɛ3/ɛ3 | |

78 | m | 10.75 | B | ɛ3/ɛ4 | |

86 | m | 5.5 | A | ɛ2/ɛ3 | |

Braak III | 68 | f | 4.5 | A | ɛ3/ɛ3 |

71 | m | 7.5 | 0 | ɛ2/ɛ3 | |

73 | m | 4 | 0 | ɛ3/ɛ3 | |

76 | f | 4 | B | ɛ3/ɛ3 | |

77 | m | 13.5 | C | ɛ3/ɛ4 | |

77 | m | 5.5 | A | ɛ3/ɛ3 | |

79 | f | 3.5 | B | ɛ3/ɛ3 | |

82 | f | 5 | A | ɛ3/ɛ3 | |

90 | f | 4 | B | ɛ3/ɛ3 | |

Braak IV | 79 | m | 5 | A | ɛ4/ɛ4 |

81 | f | 5 | C | ɛ3/ɛ3 | |

85 | m | 14 | B | ɛ3/ɛ4 | |

89 | m | 3.5 | B | ɛ3/ɛ4 | |

99 | f | 5 | B | ɛ3/ɛ3 | |

Braak V | 72 | m | 2.75 | C | ɛ3/ɛ4 |

73 | m | 4.5 | B | ɛ3/ɛ4 | |

74 | f | 9 | A | ɛ3/ɛ4 | |

75 | m | 11.5 | B | ɛ3/ɛ4 | |

77 | m | 16 | C | ɛ3/ɛ3 | |

78 | m | 17 | 0 | ɛ3/ɛ3 | |

81 | f | 5.5 | C | ɛ3/ɛ4 | |

87 | m | 7 | C | ɛ3/ɛ3 | |

93 | m | 3 | C | ɛ3/ɛ3 | |

Braak VI | 56 | f | 7 | C | ɛ3/ɛ3 |

67 | f | 8 | C | ɛ3/ɛ4 | |

86 | f | 20.5 | C | ɛ3/ɛ3 |